Baricitinib Impurity 91;2102104-37-8
=
WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com
Product Number: B026091
English Name: Baricitinib Impurity 91
English Alias: tert-butyl 3-(cyanomethyl)-3-(4-(7-((pivaloyloxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidine-1-carboxylate
CAS Number: 2102104-37-8
Molecular Formula: C₂₅H₃₁N₇O₄
Molecular Weight: 493.56
As a key impurity of baricitinib, the study of Baricitinib Impurity 91 is of great significance. Researching this impurity allows for an in-depth analysis of the synthesis process of baricitinib, identifying the nodes where impurities are generated, thereby optimizing the production process, reducing impurity formation, and increasing the purity of the main drug. As an impurity reference standard, it can accurately determine the content of this impurity in drugs, strictly control drug quality, and ensure the safety and effectiveness of drugs. In addition, research on its properties and potential hazards can provide a scientific basis for the formulation and supervision of drug quality standards.
It is mainly applied in the research, development, and quality control of baricitinib-related drugs. During the research and development process, as an impurity reference standard, it helps researchers accurately identify and quantify Baricitinib Impurity 91 in drugs to evaluate drug quality. In the quality control process, as a standard substance, it is used to establish and validate detection methods, ensuring that the content of this impurity meets the specified standards in all aspects of drug production, storage, and circulation, and contributing to the improvement and enhancement of drug quality standards.
Baricitinib, a JAK inhibitor used in the treatment of various immune diseases such as rheumatoid arthritis and atopic dermatitis, plays an important role in clinical treatment. With the increasing requirements for drug quality and safety, impurity research has become a crucial part of the drug research and production process. Baricitinib Impurity 91, as an impurity that may be generated during the synthesis or storage of baricitinib, its content and properties directly affect the quality of baricitinib drugs. Therefore, the research on this impurity has received high attention from the pharmaceutical industry.
Currently, research on Baricitinib Impurity 91 is carried out in multiple aspects. In terms of synthesis, researchers are actively exploring efficient, stable, and low-cost synthesis methods to obtain impurities with sufficient purity and quantity for subsequent research. In detection technologies, advanced techniques such as high-performance liquid chromatography-mass spectrometry (HPLC-MS) and nuclear magnetic resonance (NMR) are continuously being tried to improve the sensitivity and accuracy of impurity detection. In toxicological research, animal experiments and in vitro cell experiments are used to evaluate the potential toxicity and action mechanisms of this impurity on the human body. At the same time, research on its formation mechanisms and control strategies during the production of baricitinib is also continuously deepening, aiming to minimize impurity content and ensure drug quality and safety.
NOTE！
We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!
WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com
NEW IN STOCK!
The Molcoo Laboratory added drug impurity reference standards, including Baricitinib, Piperazine, Benzylpenicillin, Tranilast and multiple N-Nitroso drug impurities! Now available for immediate delivery!
China
